U 74500A

Drug Profile

U 74500A

Latest Information Update: 20 Jul 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmacia Corporation
  • Class Anti-ischaemics; Antiulcers; Nootropics
  • Mechanism of Action Antioxidants; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cerebral ischaemia; Cognition disorders; Craniocerebral trauma; Glioma; Myocardial infarction; Peptic ulcer; Spinal cord injuries; Transplant rejection

Most Recent Events

  • 20 Jul 2011 Discontinued - Preclinical for Cerebral ischaemia in USA (unspecified route)
  • 20 Jul 2011 Discontinued - Preclinical for Cognition disorders in USA (unspecified route)
  • 20 Jul 2011 Discontinued - Preclinical for Craniocerebral-trauma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top